Caracterización de reacciones adversas de medicamentos derivados de enzimas ocurridas en Bogotá D. C. durante el periodo 2008-2018

dc.contributorSabogal Carmona, Juan Sebastián, dir.
dc.creatorSánchez Triana, Jhoan Nicolás
dc.creatorCadena Romero, Nicolás
dc.date.accessioned2019-04-25T15:10:21Z
dc.date.available2019-04-25T15:10:21Z
dc.date.created2019-04-25T15:10:21Z
dc.date.issued2019
dc.identifierhttps://repository.udca.edu.co/handle/11158/1372
dc.identifierQF014 S15c 2019 (205475)
dc.description.abstractOne of the most important advances in modern medicine is the development of molecular biology with an emphasis on genetics, the advance has been so important that today enzymes can be isolated, such as agalsidase Alfa, agalsidase Beta, Alglucosidase, Asparaginase, Streptokinase, Idursulfase, Imiglucerase, Laronidase and Tenecteplase. These drugs are used for enzymatic, antineoplastic and thrombolytic replacement therapy, for which it is necessary to conduct a pharmacovigilance study, in which the different adverse reactions to them were analyzed. The information collected were 231 cases, in which they presented 4 PRM and 227 RAM, the highest incidence occurs in men, where a significant number of cases are in an age range between 0 to 5 years old. In most cases, reactions associated with an immune response were determined. 7
dc.description.abstractUno de los avances más importantes de la medicina moderna es el desarrollo de la biología molecular con énfasis en genética, el avance ha sido tan importante que hoy en día se pueden aislar enzimas, como lo son agalsidasa Alfa, agalsidasa Beta, Alglucosidasa, Asparaginasa, Estreptoquinasa, Idursulfasa, Imiglucerasa, Laronidasa y Tenecteplasa. Estos medicamentos son usados para terapia de reemplazo enzimático, antineoplásico y trombolítico, por lo cual es necesario realizar un estudio de farmacovigilancia, en el cual se analizó las diferentes reacciones adversas a estos. De acuerdo con la información recolectado se obtuvo 231 casos, en los cuales presentaron 4 PRM y 227 RAM, la mayor incidencia se presenta en hombres, donde una cantidad significativa de los casos se encuentran en un rango de edad entre 0 a 5 años, también en la mayoría de los casos se determinó reacciones asociadas a respuesta inmune.
dc.languagespa
dc.publisherBogotá : Universidad de Ciencias Aplicadas y Ambientales, 2019
dc.publisherFacultad de Ciencias
dc.publisherQuímica Farmacéutica
dc.relationAmorin, M. (2012). Mucopolisacaridosis de tipo I hurler: Informe de un caso. Archivos Argentinos De Pediatria, 110(5), 103-106. doi:10.5546/aap.2012.e103
dc.relationAronson, J. K. (2016). Meyler's side effects of drugs. Amsterdam: Elsevier.
dc.relationBanerjee, A., Banerjee, U. C., & Chisti, Y. (2004). Streptokinase—a clinically useful thrombolytic agent. Biotechnology Advances, 22(4), 287-307. doi:10.1016/j.biotechadv.2003.09.004
dc.relationBenedí, J., & Gómez Del Río, M. Ángeles. (2006). Fármacos antineoplásicos (I). Farmacia Profesional, 20(2), 60-65. Retrieved from http://www.elsevier.es/esrevista-farmacia-profesional-3-articulo-farmacos-antineoplasicos-i--13084621
dc.relationBiofactor GmbH. (2015). Streptokinase 1,500,000 iu - summary of product characteristics (SmPC) - (eMC). Retrieved from https://www.medicines.org.uk/emc/product/4256/smpc#AUTHDATE
dc.relationBIOMARIN PHARMACEUTICAL INC. (2008). Aldurazyme (laronidase) biomarin pharmaceutical inc. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/larobio043003LB. pdf
dc.relationBioMarin Pharmaceutical Inc. (2008). Aldurazyme epar product information es. Retrieved from https://www.ema.europa.eu/documents/productinformation/aldurazyme-epar-product-information_es.pdf
dc.relationBoehringer Ingelheim International GmbH. (2008). Metalyse epar product information en. Retrieved from https://www.ema.europa.eu/documents/product-information/metalyse-eparproduct-information_en.pdf
dc.relationCacho-Díaz, B., Lorenzana-Mendoza, N. A., Reyes-Soto, G., Hernández-Estrada, A., Monroy-Sosa, A., Guraieb-Chahin, P., & Cantu-de-León, D. (2018). Lactate deshydrogenase as a pronostic marker in neoplastic meningitis. Journal of Clinical Neuroscience, 51, 39-42. doi:10.1016/j.jocn.2018.02.014
dc.relationCarrascosa, J. M. (2012). Inmunogenicidad en terapia biológica. Implicaciones en Dermatología. Actas Dermo-Sifiliográficas, 104(6), 471-479. doi:10.1016/j.ad.2013.02.005 Retrieved from https://www.clinicalkey.es/playcontent/1-s2.0-S0001731013000999
dc.relationClínica universidad de Navarra. (2018a). ¿Qué es trombolítico? Retrieved from https://www.cun.es/diccionario-medico/terminos/trombolitico
dc.relationClínica universidad de Navarra. (2018b). Diagnóstico y tratamiento del infarto de miocardio en la clínica. Retrieved from https://www.cun.es/enfermedadestratamientos/enfermedades/infarto-miocardio
dc.relationConsulta registro invima. Retrieved from http://consultaregistro.invima.gov.co:8082/Consultas/consultas/consreg_encab cum.jsp
dc.relationDingman, R., & Balu-Iyer, S. V. (2018). Immunogenicity of protein pharmaceuticals doi:2131/10.1016/j.xphs.2018.12.014
dc.relationDingman, R., & Balu-Iyer, S. V. (2018). Immunogenicity of protein pharmaceuticals doi:2131/10.1016/j.xphs.2018.12.014
dc.relationEl-Gharbawy, A. H., Mackey, J., DeArmey, S., Westby, G., Grinnell, S. G., Malovrh, P., . . . Kishnani, P. S. (2011). An individually, modified approach to desensitize infants and young children with pompe disease, and significant reactions to alglucosidase alfa infusions doi:2131/10.1016/j.ymgme.2011.07.004
dc.relationFernandes, Q. (2016). MicroRNA: Defining a new niche in leukemia. Blood Reviews, 31(3), 129-138. doi:10.1016/j.blre.2016.11.003
dc.relationGarcía Díaz, J.D.|Mesa Latorre, J.M.|Corps Fernández, D.|Valbuena Parra, A. (2016). Enfermedades por depósito lisosomal. Medicine - Programa de Formación Médica Continuada Acreditado, 12(19), 1072-1081. doi:10.1016/j.med.2016.09.020 Retrieved from https://www.clinicalkey.es/playcontent/1-s2.0-S0304541216301664
dc.relationGenzyme Europe, B. V. (2008). Fabrazyme epar product information es. Retrieved from https://www.ema.europa.eu/documents/product-information/fabrazymeepar-product-information_es.pdf
dc.relationGenzyme Europe, B. V. (2011). Myozyme epar product information es. Retrieved from https://www.ema.europa.eu/documents/product-information/myozymeepar-product-information_es.pdf
dc.relationGenzyme Ltd. (2018). Cerezyme epar product information es. Retrieved from https://www.ema.europa.eu/documents/product-information/cerezyme-eparproduct-information_es.pdf
dc.relationGenzyme, a Sanofi company (Sanofi-Aventis S. A). (2018). ¿Qué es la enfermedad de pompe? | pompe.es. Retrieved from https://www.pompe.es/es/hcp/que-es-la-enfermedad-de-pompe#
dc.relationGiugliani, R., Rojas, V. M., Martins, A. M., Valadares, E. R., Clarke, J. T. R., Góes, J. E. C., . . . Cox, G. F. (2009). A dose-optimization trial of laronidase (aldurazyme ®) in patients with mucopolysaccharidosis I. Molecular Genetics and Metabolism, 96(1), 13-19. doi:10.1016/j.ymgme.2008.10.009
dc.relationHollak, C. E. M., vom Dahl, S., Aerts, J. M. F. G., Belmatoug, N., Bembi, B., Cohen, Y., . . . Cox, T. M. (2010). Force majeure: Therapeutic measures in response to restricted supply of imiglucerase (cerezyme) for patients with gaucher disease. Blood Cells, Molecules and Diseases, 44(1), 41-47. doi:10.1016/j.bcmd.2009.09.006
dc.relationINSERM US14. (a). Orphanet: Enfermedad de gaucher tipo 3. Retrieved from https://www.orpha.net/consor4.01/www/cgibin/Disease_Search.php?lng=ES&data_id=11104&Disease_Disease_Search_ diseaseGroup=Gaucher-tipo3&Disease_Disease_Search_diseaseType=Pat&Enfermedad(es)%2Fgrupo%2 0de%20enfermedades=Enfermedad-de-Gaucher-tipo3&title=Enfermedad%20de%20Gaucher%20tipo%203&search=Disease_Sear ch_Simple&fbclid=IwAR3paij394n1EbaXpd3C6cWMT6Gu3v7IRKTyOczyIfJiZl7Uhrewn5ic3E
dc.relationINSERM US14. (b). Orphanet: Mucopolisacaridosis tipo 1. Retrieved from https://www.orpha.net/consor4.01/www/cgibin/Disease_Search.php?lng=ES&data_id=132&Disease_Disease_Search_dis easeGroup=Mucopolisacaridosis-tipo1&Disease_Disease_Search_diseaseType=Pat&Enfermedad(es)/grupo%20de %20enfermedades=Mucopolisacaridosis-tipo1&title=Mucopolisacaridosis%20tipo%201&search=Disease_Search_Simple
dc.relationINSERM US14. (2001). Orphanet: Enfermedad de fabry. Retrieved from https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=324&lng=ES
dc.relationKesselheim, A. S., Wang, B., Franklin, J. M., & Darrow, J. J. (2015). Trends in utilization of FDA expedited drug development and approval programs, 1987- 2014: Cohort study. BMJ : British Medical Journal, 351, h4633. doi:10.1136/bmj.h4633
dc.relationKim, H., Kim, D., Hong, J., Lee, K., Seo, J., & Oh, B. H.Structural insights of idursulfase beta. To be Published, doi:10.2210/pdb6ioz/pdb
dc.relationKIM, J., & PARK, H. (2012). Unilateral femoral arterial thrombosis in a dog with malignant mammary gland tumor: Clinical and thermographic findings, and successful treatment with local intra-arterial administration of streptokinase. Journal of Veterinary Medical Science, 74(5), 657-661. doi:10.1292/jvms.11- 0432
dc.relationKose, M. D., Canda, E., Kağnıcı, M., Uçar, S. K., Onay, H., Yıldırım Sozmen, E., . . . Çoker, M. (2018). Coexistence of gaucher disease and severe congenital neutropenia. Blood Cells, Molecules and Diseases, doi:10.1016/j.bcmd.2018.07.001
dc.relationKyriakopoulos, S., & Kontoravdi, C. (2013). Analysis of the landscape of biologically-derived pharmaceuticals in europe: Dominant production systems, molecule types on the rise and approval trends. European Journal of Pharmaceutical Sciences, 48(3), 428-441. doi:10.1016/j.ejps.2012.11.016
dc.relationMarini, B. L., Perissinotti, A. J., Bixby, D. L., Brown, J., & Burke, P. W. (2017). Catalyzing improvements in ALL therapy with asparaginase. Blood Reviews, 31(5), 328-338. doi:10.1016/j.blre.2017.06.002
dc.relationMoumneh, T., Penaloza, A., & Roy, P. M. (2018). Trombosis venosa profunda doi:2131/10.1016/S1636-5410(17)87867-3
dc.relationMuenzer, J., Burton, B. K., Harmatz, P., Botha, J., & Kampmann, C. (2019). Evaluation of the long-term treatment effects of idursulfase using statistical modelling: Data from the hunter outcome survey (HOS) doi://doi.org/10.1016/j.ymgme.2018.12.261
dc.relationNavarrete-Meneses, M. d. P., & Pérez-Vera, P. (2017). Alteraciones epigenéticas en leucemia linfoblástica aguda. Boletín Médico Del Hospital Infantil De México, 74(4), 243-264. doi:10.1016/j.bmhimx.2017.02.005
dc.relationOrganización Panamericana de la Salud. (2010). Red PARF documento técnico no. 5 buenas prácticas de farmacovigilancia para las américas. Retrieved from http://apps.who.int/medicinedocs/documents/s18625es/s18625es.pdf
dc.relationPérez-López, J., Moltó-Abad, M., Muñoz-Delgado, C., Morales-Conejo, M., Ceberio-Hualde, L., & del Toro, M. (2018). Efficacy of idursulfase therapy in patients with mucopolysaccharidosis type II who initiated enzyme replacement therapy in adult age. A systematic review of the literature. Molecular Genetics and Metabolism, 124(3), 216-227. doi:10.1016/j.ymgme.2018.04.013
dc.relationPulido Pérez, A., & Suárez Fernández, R. (2014). Enfermedades bullosas doi:2131/10.1016/S0304-5412(14)70696-1
dc.relationRamaswami, U. (2011). Update on role of agalsidase alfa in management of fabry disease. Drug Design, Development and Therapy, 5, 155-173. doi:10.2147/DDDT.S11985
dc.relationRESERVADOS, INSERM US14-- TODOS LOS DERECHOS.Orphanet: Mucopolisacaridosis tipo 2. Retrieved from https://www.orpha.net/consor4.01/www/cgibin/Disease_Search.php?lng=ES&data_id=131&Disease_Disease_Search_dis easeGroup=Hunter&Disease_Disease_Search_diseaseType=Pat&Enfermeda d(es)/grupo%20de%20enfermedades=Mucopolisacaridosis-tipo2&title=Mucopolisacaridosis%20tipo%202&search=Disease_Search_Simple
dc.relationRodríguez Morales, I., Valdés, Y. C., & Proveyer Derich, S. (2004). Citostáticos: Medicamentos riesgosos. Revista Cubana De Medicina, 43(2-3), 0-0. Retrieved from http://scielo.sld.cu/scielo.php?script=sci_abstract&pid=S0034- 75232004000200009&lng=es&nrm=iso&tlng=es
dc.relationSabogal Carmona, J. S., Díaz Rodríguez, E. A., Espinosa Espinosa, I. I. & Línea de Acción Medicamentos Seguros de Bogota. (2013). Fundamentos de farmacovigilancia. Retrieved from http://biblioteca.saludcapital.gov.co/img_upload/57c59a889ca266ee6533c26f9 70cb14a/documentos/FUNDAMENTOS_FARMACOVIG.pdf
dc.relationSauna, Z. E., Lagassé, D., Pedras-Vasconcelos, J., Golding, B., & Rosenberg, A. S. (2018). Evaluating and mitigating the immunogenicity of therapeutic proteins doi:2131/10.1016/j.tibtech.2018.05.008
dc.relationSchuller, Y., Arends, M., Körver, S., Langeveld, M., & Hollak, C. E. M. (2018). Adaptive pathway development for fabry disease: A clinical approach. Drug Discovery Today, 23(6), 1251-1257. doi:10.1016/j.drudis.2018.02.004
dc.relationShire Human Genetic Therapies, A B.Replagal epar product information es. Retrieved from https://www.ema.europa.eu/documents/productinformation/replagal-epar-product-information_es.pdf
dc.relationShire Human Genetic Therapies, Inc. (2015). Elapraseinf. Retrieved from https://medsafe.govt.nz/profs/datasheet/e/elapraseinf.pdf
dc.relationShrivastava, Abhinav|Khan, Abdul Arif|Khurshid, Mohsin|Kalam, Mohd Abul|Jain, Sudhir K.|Singhal, Pradeep K. (2015). Recent developments in l -asparaginase discovery and its potential as anticancer agent. Critical Reviews in Oncology and Hematology, 100, 1-10. doi:10.1016/j.critrevonc.2015.01.002
dc.relationSociedad Española de Medicina Interna. (2015). Embolia pulmonar. Retrieved from https://www.fesemi.org/informacion-pacientes/conozca-mejor-suenfermedad/embolia-pulmonar
dc.relationTsuji, K., & Tsutani, K. (2008). Approval of new biopharmaceuticals 1999–2006: Comparison of the US, EU and japan situations. European Journal of Pharmaceutics and Biopharmaceutics, 68(3), 496-502. doi:10.1016/j.ejpb.2007.07.013
dc.relationUniversidad nacional autónoma de México. (2018). La medicina moderna (siglos xix y xx). Retrieved from http://bibliotecadigital.ilce.edu.mx/sites/ciencia/volumen3/ciencia3/154/html/sec _16.htm
dc.relationVedder, A. C., Breunig, F., Donker-Koopman, W. E., Mills, K., Young, E., Winchester, B., . . . Hollak, C. E. M. (2008). Treatment of fabry disease with different dosing regimens of agalsidase: Effects on antibody formation and GL3 doi:2131/10.1016/j.ymgme.2008.03.003
dc.relationVermeer, F. (2001). Thrombolytic therapy in patients of female gender doi:2131/10.1016/S0049-3848(01)00305-X
dc.relationVigiBase. (2018). Vigiaccess. Retrieved from http://www.vigiaccess.org/
dc.relationVizcaíno, M., Lopera, J. E., Martínez, L., De los Reyes, I., & Linares, A. (2016). Guía de atención integral para la detección oportuna, diagnóstico, tratamiento y seguimiento de leucemia linfoide aguda en niños, niñas y adolescentes. Revista Colombiana De Cancerología, 20(1), 37-39. doi:10.1016/j.rccan.2015.08.003
dc.relationWacker Biotech GmbH. (2016). Spectrila epar product information es. Retrieved from https://www.ema.europa.eu/documents/product-information/spectrilaepar-product-information_es.pdf
dc.relationWHO Collaborating Centre for Drug Statistics Methodology. (2009). WHOCC - ATC/DDD index. Retrieved from https://www.whocc.no/atc_ddd_index/
dc.relationWishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., . . . Wilson, M. (2018). DrugBank 5.0: A major update to the DrugBank database for 2018. Nucleic Acids Research, 46(D1), D1082. doi:10.1093/nar/gkx1037
dc.relationZimran, A., Morris, E., Mengel, E., Kaplan, P., Belmatoug, N., Hughes, D. A., . . . vom Dahl, S. (2009). The female gaucher patient: The impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause). Blood Cells, Molecules and Diseases, 43(3), 264- 288. doi:10.1016/j.bcmd.2009.04.003
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/4.0/
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAtribución-NoComercial-CompartirIgual 4.0 Internacional (CC BY-NC-SA 4.0)
dc.rightsDerechos Reservados - Universidad de Ciencias Aplicadas y Ambientales, 2019
dc.titleCaracterización de reacciones adversas de medicamentos derivados de enzimas ocurridas en Bogotá D. C. durante el periodo 2008-2018
dc.typeTrabajo de grado - Pregrado


Este ítem pertenece a la siguiente institución